IL238566A0 - Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates - Google Patents

Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates

Info

Publication number
IL238566A0
IL238566A0 IL238566A IL23856615A IL238566A0 IL 238566 A0 IL238566 A0 IL 238566A0 IL 238566 A IL238566 A IL 238566A IL 23856615 A IL23856615 A IL 23856615A IL 238566 A0 IL238566 A0 IL 238566A0
Authority
IL
Israel
Prior art keywords
antibody
receptor
alpha
antibodies against
drug conjugates
Prior art date
Application number
IL238566A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL238566A0 publication Critical patent/IL238566A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL238566A 2012-11-07 2015-04-30 Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates IL238566A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261723545P 2012-11-07 2012-11-07
US201361749610P 2013-01-07 2013-01-07
US201361886156P 2013-10-03 2013-10-03
US201361889179P 2013-10-10 2013-10-10
PCT/IB2013/059786 WO2014072888A1 (en) 2012-11-07 2013-10-30 Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates

Publications (1)

Publication Number Publication Date
IL238566A0 true IL238566A0 (en) 2015-06-30

Family

ID=49955428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238566A IL238566A0 (en) 2012-11-07 2015-04-30 Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates

Country Status (15)

Country Link
US (1) US9828428B2 (en:Method)
EP (1) EP2916875A1 (en:Method)
JP (1) JP2016503295A (en:Method)
KR (1) KR101763499B1 (en:Method)
CN (1) CN104936621A (en:Method)
AU (1) AU2013343111A1 (en:Method)
CA (1) CA2890256A1 (en:Method)
HK (1) HK1214161A1 (en:Method)
IL (1) IL238566A0 (en:Method)
MX (1) MX2015005582A (en:Method)
PE (1) PE20150891A1 (en:Method)
PH (1) PH12015500977A1 (en:Method)
RU (1) RU2015116485A (en:Method)
SG (1) SG11201503431TA (en:Method)
WO (1) WO2014072888A1 (en:Method)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6502959B2 (ja) * 2013-12-12 2019-04-17 上海恒瑞医薬有限公司 Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
US20170190735A1 (en) 2014-05-28 2017-07-06 Agensys, Inc. Derivatives of dolaproine-dolaisoleuine peptides
CN106414497B (zh) 2014-05-29 2021-07-27 宏观基因有限公司 三特异性结合分子和其使用方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
KR20240091253A (ko) 2015-02-16 2024-06-21 론자 리미티드 Cl 및/또는 ch1 돌연변이된 약물 접합용 항체
AU2016326449B2 (en) 2015-09-21 2024-10-31 Aptevo Research And Development Llc CD3 binding polypeptides
CA2949032A1 (en) 2015-11-30 2017-05-30 Pfizer Inc. Site specific her2 antibody drug conjugates
TWI637966B (zh) * 2015-11-30 2018-10-11 輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
CN107405408B (zh) * 2015-12-21 2021-07-02 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
SG11201805420SA (en) * 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
CN109310762A (zh) 2016-06-07 2019-02-05 宏观基因有限公司 联合疗法
CN108456250B (zh) 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
CN107880131A (zh) * 2017-08-14 2018-04-06 四川大学 一种抗IL‑13Rα2和CD3双特异抗体及其应用
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
CN111465618A (zh) 2017-12-12 2020-07-28 宏观基因有限公司 双特异性cd16-结合分子及其在疾病治疗中的用途
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
SG11202008795SA (en) * 2018-03-14 2020-10-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
MX2020009464A (es) 2018-03-14 2021-01-15 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Inmunoterapia de células t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13.
CN113423730B (zh) * 2019-02-15 2024-01-05 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
US12435155B2 (en) 2020-02-21 2025-10-07 Macrogenics, Inc. CD137 binding molecules and uses thereof
CN115427455A (zh) * 2020-05-15 2022-12-02 埃利塞拉疗法公司 抗IL13Rα2抗体、其抗原结合片段和用途
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
TW202302641A (zh) * 2021-02-19 2023-01-16 大陸商上海齊魯製藥研究中心有限公司 針對IL-13Rα2的抗體及其應用
WO2023274384A1 (zh) 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向b7h3的抗原结合多肽及其应用
JP2024527539A (ja) 2021-07-01 2024-07-25 寧波茂行生物医薬科技有限公司 ＩＬ１３Ｒα２を標的としたユニバーサルＣＡＲ－Ｔ細胞及びその製造方法と使用
WO2023155796A1 (en) * 2022-02-17 2023-08-24 Lanova Medicines Development Co., Ltd. Anti-il-13ra2 monoclonal antibodies and uses thereof
WO2024041650A1 (en) * 2022-08-25 2024-02-29 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
CN115960257B (zh) * 2022-09-29 2023-10-27 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的经优化的嵌合抗原受体及其用途
WO2024071397A1 (ja) * 2022-09-30 2024-04-04 国立大学法人 東京大学 Ｉｌ１３ｒａ２に標的化した単純ヘルペスウイルス及び抗ｉｌ１３ｒａ２抗体またはその抗原結合断片

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2002017968A2 (en) 2000-08-31 2002-03-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
WO2005042028A2 (en) 2003-10-27 2005-05-12 Neopharm, Inc. Il-13 conjugated to an immunogen and uses thereof
JP2010507365A (ja) 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド 抗ＩＬ−１３Ｒα１抗体およびその使用
ES2658239T3 (es) 2006-10-19 2018-03-08 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina-13
JP2010190572A (ja) 2007-06-01 2010-09-02 Sapporo Medical Univ ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
CN103096933A (zh) 2010-07-12 2013-05-08 CovX科技爱尔兰有限公司 多功能抗体缀合物
AR088694A1 (es) 2011-11-17 2014-06-25 Pfizer Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TW201341401A (zh) 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛

Also Published As

Publication number Publication date
JP2016503295A (ja) 2016-02-04
US20150266962A1 (en) 2015-09-24
US9828428B2 (en) 2017-11-28
RU2015116485A (ru) 2016-12-27
MX2015005582A (es) 2015-08-14
KR101763499B1 (ko) 2017-07-31
EP2916875A1 (en) 2015-09-16
PE20150891A1 (es) 2015-06-11
PH12015500977A1 (en) 2015-07-13
KR20150060980A (ko) 2015-06-03
HK1214161A1 (zh) 2016-07-22
CN104936621A (zh) 2015-09-23
SG11201503431TA (en) 2015-05-28
AU2013343111A1 (en) 2015-05-14
WO2014072888A1 (en) 2014-05-15
CA2890256A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
IL238566A0 (en) Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
CY2023013I2 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης
IL278658B (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
IL238567A0 (en) Antibodies against notch3 and antibody-drug conjugates
IL243665A0 (en) Humanized il-6 and il-6 receptor
ZA201706241B (en) Anti-cxcr4 antibodies and antibody-drug conjugates
IL240438A0 (en) New antibody conjugates and their uses
IL246277A0 (en) Peptide-mimicking compounds and their antibody-drug conjugates
ZA201603697B (en) Peptidomimetic compounds and antibody-drug conjugates thereof
IL241277A0 (en) Antibody drug conjugates
PL2906251T3 (pl) Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
DK2288570T3 (da) Arreteringsindretning
CL2015000027A1 (es) Anticuerpos e inmunoconjugados anti-cd22
EP2823807A4 (en) SUN PROTECTION COMPOSITION
IL227477A0 (en) Human antibodies and antibody-drug conjugates against 74cd
EP2970511A4 (en) INSULIN CONJUGATES incretin
PT3003386T (pt) Conjugados anticorpo-fármaco
EP2826790A4 (en) GREMLIN-1 ANTIBODY
EP2917244A4 (en) ANTIBODY CONJUGATES OBTAINED FROM APROTININE
CL2014003125A1 (es) Anticuerpos de anti-transglutaminasa 2
IL245437A0 (en) Antibodies against efna4 and antibody-drug pairs
EP2925760A4 (en) C20'-UREA DERIVATIVES OF VINCALAL ALCOHOLS
ITFI20100031U1 (it) Pantaloni con vestibilita' regolabile
ITSS20130009U1 (it) "il pannello fotoeolico"
BR302012005912S1 (pt) " configuração aplicada em suporte "